The vulnerable endothelium - Priming the vascular endothelium for thrombosis with unfractionated heparin: Biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GIYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial

American Heart Journal

Volumn 150, Issue 2, 2005, Pages 189-192

  Becker, Richard C ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

BLOOD FLOW; CLINICAL TRIAL; EDITORIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOSIS; TISSUE PERFUSION; VASCULAR ENDOTHELIUM;

ANTICOAGULANTS; CORONARY DISEASE; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LIPOPROTEINS; META-ANALYSIS; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; PREMEDICATION; RANDOMIZED CONTROLLED TRIALS; THROMBOPHILIA; THROMBOSIS; VASCULITIS;

EID: 23644446481     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.04.006     Document Type: Editorial

References (35)

1. J.J. Ferguson, R.M. Califf, and E.M. Antman Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
2. J.L. Petersen, K.W. Mahaffey, and V. Hasselblad Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview JAMA 292 2004 89 96
3. A. Tedgui, and Z. Mallat Anti-inflammatory mechanisms in the vascular wall Circ Res 88 2001 877 887
4. P. Kubes, M. Suzuki, and D.N. Granger Nitric oxide: an endogenous modulator of leukocyte adhesion Proc Natl Acad Sci U S A 88 1991 4651 4655
5. H.M. Honda, N. Leitinger, and M. Frankel Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites Arterioscler Thromb Vasc Biol 19 1999 680 686
6. P.C. Kouretas, Y.D. Kim, and P.A. Cahill Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog Circulation 99 1999 1062 1068
7. K. Yokokawa, H. Tahara, and M. Kohno Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells J Clin Invest 92 1993 2080 2085
8. B. Felzen, G. Berke, and P. Gardner Involvement of the IP3 cascade in the damage to guinea-pig ventricular myocytes induced by cytotoxic T lymphocytes Eur J Physiol 433 1997 721 726
9. K. Riesenberg, F. Schlaeffer, and A. Katz Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents Br Heart J 73 1995 14 19
10. G. Montalescot, F. Philippe, and A. Ankri Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French investigators of the ESSENCE trial Circulation 98 1998 294 299
11. S.K. James, A. Siegbahn, and P. Armstrong Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy Am Heart J 147 2004 267 274
12. J.D. Marmur, S.V. Thurivakramm, and B.S. Fyfe Identification of active tissue factor in human coronary atheroma Circulation 94 1996 1226 1232
13. B.H. Annex, S.M. Denning, and K.M. Channon Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes Circulation 91 1995 619 622
14. V. Toschi, R. Gallo, and M. Lettino Tissue factor modulates the thrombogenicity of human atherosclerotic plaques Circulation 95 1997 594 599
15. M.S. Bajaj, J.J. Birktoft, and S.A. Steer Structure and biology of tissue factor pathway inhibitor Thromb Haemost 86 2001 959 972
16. M.S. Bajaj, M.N. Kuppuswamy, and A.N. Manepalli Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues Thromb Haemost 82 1999 1047 1052
17. C. Lupu, F. Lupu, and U. Dennehy Thrombin induces the redistribution and acute release of tissue factor inhibitor from specific granules within human endothelial cells in culture Arterioscler Thromb Vasc Biol 15 1995 2055 2062
18. P. Golino, A. Ravera, and M. Ragni Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes Circulation 108 2003 2864 2869
19. S. Valentin, O. Nordfang, and C. Bregengard Evidence that the C-terminus for tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins Blood Coagul Fibrinolysis 4 1993 713 720
20. J.B. Hansen, B. Svensson, and R. Olsen Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro Thromb Haemost 83 2000 937 943
21. Y. Li, M. Rodriguez, and F.A. Spencer Comparative effects of unfractionated heparin and low molecular weight heparin on vascular tissue factor pathway release: a model for assessing intrinsic thromboresistance J Thromb Thrombolysis 14 2003 123 129
22. J.B. Hansen, P.M. Sandset, and K.R. Huseby Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man Thromb Haemost 76 1996 703 709
23. C. Lupu, E. Poulsen, and S. Roquefeuil Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture Arterioscler Thromb Vasc Biol 19 1999 2251 2262
24. R.C. Becker, F.A. Spencer, and Y. Li Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes J Am Coll Cardiol 34 1999 1020 1027
25. P. Theroux, H. Ouimet, and J. McCans Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 319 1988 1105 1111
26. M.C. Bahit, E.J. Topol, and R.M. Califf Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb J Am Coll Cardiol 37 2001 1001 1007
27. TRIM Study Group A low molecular weight, selective thrombin inhibitor, inogatran vs heparin, in unstable coronary artery disease in 1,209 patients: a double-blind, randomized, dose-finding study Eur Heart J 18 1997 1416 1425
28. M.A. Lauer, P.L. Houghtaling, and J.G. Peterson Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes. Observations from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial Circulation 104 2001 1772 1777
29. S. Alban, and R. Gastpar Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins Thromb Haemost 85 2001 824 829
30. J.R. Brown, and D.J. Kuter The effect of unfractionated vs low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients Thromb Haemost 85 2001 979 985
31. J.-B. Hansen, P.M. Sandset, and K.R. Huseby Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action Br J Haematol 101 1998 638 646
32. H. Kato Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects Arterioscler Thromb Vasc Biol 22 2002 539 548
33. J.R. Brown, and D.J. Kuter The effect of unfractionated vs low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients Thromb Haemost 85 2001 979 985
34. S.G. Goodman, A. Barr, and A. Sobtchouk Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy J Am Coll Cardiol 36 2000 1507 1513
35. Z. Xiao, and P. Théroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256